Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Phyrago, an oral kinase inhibitor used to treat chronic myeloid leukemia and acute lymphoblastic leukemia; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis and heartburn associated with symptomatic non-erosive gastroesophageal reflux disease; HND-004 for treating diabetes; Varenicline tablet and HND-032 for smoking cessation; and HND-026, a GI drug. Handa Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Tainan City, Taiwan.
Frequently asked questions
What sector does Handa Pharmaceuticals Inc. (6620) operate in?
Handa Pharmaceuticals Inc. belongs to the Other sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Handa Pharmaceuticals Inc. (6620) current stock price?
As of the latest data, Handa Pharmaceuticals Inc. stock price is NT$80.80, with a previous close of NT$80.80.
What is Handa Pharmaceuticals Inc. (6620) current market capitalization?
Handa Pharmaceuticals Inc. market cap is approximately 13.13 billion.
What is Handa Pharmaceuticals Inc. (6620) Earnings Per Share (EPS)?
The trailing EPS is NT$4.83, and the forward EPS is NT$5.11.
What is Handa Pharmaceuticals Inc. (6620) Price-to-Earnings (P/E) ratio?
Handa Pharmaceuticals Inc. current P/E ratio is 16.73, with a forward P/E of 15.81.
Does Handa Pharmaceuticals Inc. (6620) pay dividends?
Yes. Handa Pharmaceuticals Inc. pays annual dividends with an annualized yield of 2.57% and an estimated annual payout of NT$2.07 per share.
When is the next ex-dividend date for Handa Pharmaceuticals Inc. (6620)?
The next ex-dividend date is scheduled for July 06, 2027.
When is Handa Pharmaceuticals Inc. (6620) next earnings report?
Handa Pharmaceuticals Inc. is expected to release its next earnings report on March 31, 2027.
What is Handa Pharmaceuticals Inc. (6620) beta (volatility) score?
Handa Pharmaceuticals Inc. has a beta of 0.695, indicating lower volatility than the overall market.
